The United States Food and Drug Administration (FDA) has accepted a new drug application that combines the active ingredient behind Cialis with finasteride to create a daily treatment to help men with benign prostatic hyperplasia (BPH).

BPH or benign prostate enlargement is when the prostate gets larger, which can be a side effect of some kinds of erectile dysfunction and can cause issues with urination, urinary tract infections and kidney issues.

It is possible to buy Cialis to treat BPH, and indeed studies have been undertaken on the effectiveness of tadalafil on the condition, which makes it unique among PDE5-inhibitors that help treat erectile dysfunction.

However, the main medical treatment path involved the use of finasteride, a 5-alpha-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone.

Taking both medications in tandem has already been used to treat BPH and is sometimes known as Tadfin, which has 5mg of each of the two active ingredients.

However, a combined capsule medication has previously not seen approval, making it more difficult to ensure the right amounts of both medications are taken as a daily medication.

Most ED medication is taken as needed and has a half-life in the bloodstream of just a few hours. Tadalafil is different, however, and can stay in the system for over a day.

As BPH and ED both affect each other in different ways in some cases, Tadfin is a treatment intended for treating people who have both ED and BPH, particularly if they also are suffering from urinary tract issues as a result of either.

The FDA is expected to decide on whether the new drug will be approved for use by the end of the year.